pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,836 catalysts · 5,256 phase readout · 2,333 8k filing · 321 pdufa · 259 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 62 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: earnings×type: pdufa×type: phase readout×clear all
type
  • phase readout5,256
  • 8k filing2,333
  • pdufa321
  • earnings259
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›WITHDRAWNphase readoutNCT02893059: Evaluation of a Data Collection Tool in Clinical Research: Comparison Between the Data Collected by Patient Diary and Data From Medical Administrative Databases

Sponsor: Centre Hospitalier Universitaire de Nīmes. Phase: . Conditions: Case Report Form, Declaration Bias, Health Insurance Database

full page →ctgov ↗
›COMPLETEDphase readoutNCT04027296: Development and Validation of the GLORI-COPD Score

Sponsor: University of Paris 5 - Rene Descartes. Phase: . Conditions: Pulmonary Disease, Chronic Obstructive

full page →ctgov ↗
›COMPLETEDphase readoutNCT05327296: Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

Sponsor: Sedana Medical. Phase: PHASE3. Conditions: Sedation

full page →ctgov ↗
›RECRUITINGphase readoutNCT07504796: ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Sponsor: NYU Langone Health. Phase: PHASE4. Conditions: Metastatic Melanoma, Advanced Melanoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT05710679: Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Sponsor: Centre Jean Perrin. Phase: NA. Conditions: Locally Advanced Head and Neck Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06274879: Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

Sponsor: Insel Gruppe AG, University Hospital Bern. Phase: PHASE2. Conditions: Bile Duct Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT06133062: Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Sponsor: Chang Gung Memorial Hospital. Phase: PHASE2. Conditions: Hepatocellular Carcinoma Non-resectable

full page →ctgov ↗
›RECRUITINGphase readoutNCT07351227: Pediatric Airway: Noninferiority Trial of Devices for Intubation Assessment

Sponsor: University of Sao Paulo General Hospital. Phase: NA. Conditions: Intubation, Intratracheal, Airway Management, Video Laryngoscope, Cost Effectiveness

full page →ctgov ↗
›RECRUITINGphase readoutNCT07476703: Expanded Studies on the SCAPIS Stockholm Reexamination Cohort

Sponsor: Danderyd Hospital. Phase: . Conditions: Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency, Heart Failure, Pulmonary Disease, Chronic Obstructive (COPD), Steatohepatitis, Inflammation Biomarkers, Lipid Profile, Oral Microbiota, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)

full page →ctgov ↗
›COMPLETEDphase readoutNCT06204003: Cannabinoids for Pain Management and Neuroprotection From Concussion

Sponsor: University of Regina. Phase: PHASE1. Conditions: Healthy

full page →ctgov ↗
›RECRUITINGphase readoutNCT04816227: Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France. Phase: . Conditions: Amyotrophic Lateral Sclerosis

full page →ctgov ↗
›COMPLETEDphase readoutNCT05553327: Impact of a Multimodal Prehabilitation Program Before Robotic-assisted Radical Prostatectomy.

Sponsor: Hospital Clinic of Barcelona. Phase: NA. Conditions: Prostate Cancer, Radical Prostatectomy

full page →ctgov ↗
›COMPLETEDphase readoutNCT06883942: Pilot Study on the Evaluation of the Functionality, Safety and Reliability of New Tripping Devices for Lower Limbs.

Sponsor: Fondazione Don Carlo Gnocchi ETS. Phase: . Conditions: Lower Limb Amputation, Slip Perturbations, Fall Risk

full page →ctgov ↗
›COMPLETEDphase readoutNCT03155386: Optimized Angiomammography and Comparison With Standard Angiomammography

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris. Phase: . Conditions: Patients for Whom an Angiomammogram Examination is Requested Whether Its Indication

full page →ctgov ↗
›COMPLETEDphase readoutNCT05228470: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Sponsor: Pfizer. Phase: PHASE2. Conditions: Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, MagnetisMM-8

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05748873: Promising ROd-cone DYstrophy Gene therapY

Sponsor: SparingVision. Phase: PHASE1. Conditions: Retinitis Pigmentosa

full page →ctgov ↗
›RECRUITINGphase readoutNCT05471973: CIED Infection Quality Initiative Demonstration Project

Sponsor: Duke University. Phase: NA. Conditions: Infections

full page →ctgov ↗
›COMPLETEDphase readoutNCT03364569: Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.

Sponsor: Hôpital NOVO. Phase: . Conditions: Plastic Surgery

full page →ctgov ↗
›COMPLETEDphase readoutNCT05819541: Treating Exacerbations of Asthma With Oral Montelukast in Children

Sponsor: Vanderbilt University Medical Center. Phase: PHASE2. Conditions: Status Asthmaticus

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05228041: BIOlogics in Severe Nasal POlyposis SurvEy

Sponsor: University Hospital, Lille. Phase: . Conditions: Chronic Rhinosinusitis With Nasal Polyps

full page →ctgov ↗
›COMPLETEDphase readoutNCT05515341: A DirEct to PatieNt Study in Chronic Pain

Sponsor: Boston Scientific Corporation. Phase: . Conditions: Chronic Pain

full page →ctgov ↗
›RECRUITINGphase readoutNCT07512154: Precision Radiotherapy Enabled by Molecular MRI

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase: NA. Conditions: Brain Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT06273605: The Egg Up Trial - Testing a New Treatment Pathway for Infants With Newly Diagnosed Egg Allergy

Sponsor: Murdoch Childrens Research Institute. Phase: NA. Conditions: Food Allergy, Food Allergy in Infants

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05346354: Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Sponsor: Alexion Pharmaceuticals, Inc.. Phase: PHASE2. Conditions: Neuromyelitis Optica Spectrum Disorder

full page →ctgov ↗
›COMPLETEDphase readoutNCT05351905: Improving Pain Disability With the Use of Oral Cannabinoids

Sponsor: University Health Network, Toronto. Phase: NA. Conditions: Chronic Pain, Opioid Use, Cannabis

full page →ctgov ↗
›COMPLETEDphase readoutNCT07574294: Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps

Sponsor: Azienda Ulss 2 Marca Trevigiana. Phase: . Conditions: Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07615283: Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

Sponsor: Sun Yat-sen University. Phase: PHASE1. Conditions: Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL

full page →ctgov ↗
›COMPLETEDphase readoutNCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Sponsor: COVID-19 Prevention Network. Phase: . Conditions: Tuberculosis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07407894: iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

Sponsor: Synbiotic Health. Phase: NA. Conditions: Healthy Aging, Anti Aging

full page →ctgov ↗
›COMPLETEDphase readoutNCT00690066: PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Sponsor: Mesoblast, Inc.. Phase: PHASE2. Conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes

full page →ctgov ↗
›RECRUITINGphase readoutNCT07322302: RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

Sponsor: University of North Carolina, Chapel Hill. Phase: NA. Conditions: Trachoma, Eye Diseases, Trichiasis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07079631: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Sponsor: BioNTech SE. Phase: PHASE1. Conditions: Metastatic Colorectal Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT06420531: Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Prematurity

full page →ctgov ↗
›RECRUITINGphase readoutNCT04946253: SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care

Sponsor: University of Pittsburgh. Phase: NA. Conditions: Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders

full page →ctgov ↗
›TERMINATEDphase readoutNCT05175053: Early RRT in AKI After Cardiac Surgery

Sponsor: Seoul National University Hospital. Phase: NA. Conditions: Acute Kidney Injury

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07512245: Assessment of Two Soft Tissue Augmentation Using Acellular Dermis Around Dental Implants

Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Acellular Dermal Matrix, Alveolar Mucosa

full page →ctgov ↗
›COMPLETEDphase readoutNCT02583672: Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

Sponsor: University of Minnesota. Phase: PHASE2. Conditions: Gaucher Disease Type 1

full page →ctgov ↗
›COMPLETEDphase readoutNCT04804072: INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

Sponsor: HIV Prevention Trials Network. Phase: NA. Conditions: HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder

full page →ctgov ↗
›COMPLETEDphase readoutNCT01617395: Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS). Phase: . Conditions: Multiple Sclerosis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04950439: Pyrophosphate and Arterial Calcification in Chronic Kidney Disease

Sponsor: Centre Hospitalier Universitaire de Nice. Phase: NA. Conditions: Chronic Kidney Diseases

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07327177: BFR Rope Training in Male Volleyball Players

Sponsor: Karabuk University. Phase: NA. Conditions: Volleyball, Performance, Power

full page →ctgov ↗
›COMPLETEDphase readoutNCT07050875: Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting

Sponsor: ABLE Human Motion S.L.. Phase: NA. Conditions: Acquired Brain Injury (Including Stroke)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07346157: Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Sponsor: Sabine Mueller, MD, PhD. Phase: PHASE1. Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05134857: The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

Sponsor: Washington State University. Phase: PHASE2. Conditions: Alcohol Use Disorder (AUD)

full page →ctgov ↗
›RECRUITINGphase readoutNCT03972657: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Sponsor: Regeneron Pharmaceuticals. Phase: PHASE1. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

full page →ctgov ↗
›RECRUITINGphase readoutNCT06434012: Barts Endocarditis Research Registry

Sponsor: Queen Mary University of London. Phase: . Conditions: Infective Endocarditis, Endocarditis, Endocarditis, Bacterial

full page →ctgov ↗
›RECRUITINGphase readoutNCT07020312: Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery

Sponsor: Rush University Medical Center. Phase: PHASE2. Conditions: Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy

full page →ctgov ↗
›RECRUITINGphase readoutNCT07325630: Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

Sponsor: Zhejiang Cancer Hospital. Phase: PHASE2. Conditions: IBI363 + Chemotherapy

full page →ctgov ↗
›RECRUITINGphase readoutNCT00001230: Host Response to Infection and Treatment in Filarial Diseases

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Phase: . Conditions: Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06883630: A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Sponsor: RemeGen Co., Ltd.. Phase: PHASE1. Conditions: Non-Small Cell Lung Cancer

full page →ctgov ↗
← prev
page 99 of 117
next →